Big Week for #SYNGAP1: Trials, Data, #Epilepsy, Palo Alto & Athens #S10E216

Sunday, August 30, 2026 — Week 36

TRIALS & DATA — CAMP4, RARE-X + ProMMiS

CAMP4 / CMP-002

Australia and Argentina cleared.

EU and UK filings underway.

First-in-human Phase 1/2 study still targeted for Q4 2026.

CMP-002 is designed to increase expression of the healthy SYNGAP1 copy.

CAMP4 raised another $50M and reports cash runway through the end of 2028.

Q2 earnings / corporate update:https://investors.camp4tx.com/news-releases/news-release-details/camp4-reports-second-quarter-2026-financial-results-and

Rare-X + ProMMiS

Rare-X is our PRO partner for the ProMMiS Natural History Study.

IMPORTANT: Families participating in ProMMiS need to complete their Rare-X surveys within SEVEN DAYS of their ProMMiS Natural History Study visit date.